Grifols (GRFS) Financial Analysis & Valuation | Quarter Chart
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plas... more
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $6.22B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | ES | CEO | Jose Ignacio Abia Buenache |
| IPO Date | 2011-06-02 | CAGR | 14.02% |
| Employees | 25,258 | Website | www.grifols.com |
| Div. Yield | 2.99% | Payout Ratio | 28% |
| Buy Back Yield | — | Total Yield | 2.99% |
GRFS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $11.66B | P/E | 8.44 | Forward P/E | 5.1 | PEG | 0.29 |
| P/S | 0.25 | P/B | 0.34 | P/CF | 1.71 | P/FCF | 2.46 |
| Sales | $8.58B | Sales 1Y | -0.21% | Sales 3Y | 15.02% | Sales 5Y | 32.21% |
| EPS | $0.87 | EPS 1Y | 54.41% | EPS 3Y | 393.37% | EPS 5Y | -36.07% |
| Sales QoQ | 8.45% | EPS QoQ | 109.09% | Sales QoQ Avg | 0.09% | EPS QoQ Avg | 18.28% |
| Gross Margin | 37.23% | Operating Margin | 16.66% | Profit Margin | 6.09% | ROCE | 6.93% |
| ROA | 2% | ROE | 8% | Altman Z Score | 1.04 | Piotroski Score | 7 |
| Current Ratio | 2.37 | Quick Ratio | 0.81 | Cash Ratio | 0.23 | Op. CF Ratio | 0.1 |
| Debt/Equity | 1.54 | Debt/Assets | 0.42 | Lt Debt/Equity | 1.46 | Lt Debt/Cap. | 0.56 |
| Intrst Cov. | 2.31 | Inventory Turnover | 1.33 | Asset Turnover | 0.37 | Receivables Turnover | 6.24 |
| Enterprise Value | $11.66B | P/E Ratio | 8.44 |
| Forward P/E | 5.1 | PEG Ratio | 0.29 |
| P/S Ratio | 0.25 | P/B Ratio | 0.34 |
| P/CF Ratio | 1.71 | P/FCF Ratio | 2.46 |
| EPS | $0.87 | EPS Growth 1Y | 54.41% |
| EPS Growth 3Y | 393.37% | EPS Growth 5Y | -36.07% |
| Revenue Growth 1Y | -0.21% | Gross Margin | 37.23% |
| Operating Margin | 16.66% | Profit Margin | 6.09% |
| ROE | 8% | ROA | 2% |
| ROCE | 6.93% | Current Ratio | 2.37 |
| Quick Ratio | 0.81 | Cash Ratio | 0.23 |
| Debt/Equity | 1.54 | Interest Coverage | 2.31 |
| Altman Z Score | 1.04 | Piotroski Score | 7 |
Grifols (GRFS) valuation & financials
Grifols (GRFS) has a market capitalization of $6.22B and trades at a price-to-earnings ratio of 8.4. It operates in the Healthcare sector (Drug Manufacturers - General).
Grifols's revenue grew -0.2% over the last year.
Grifols's next earnings report is scheduled for November 10, 2026 (provider scheduled date); analysts estimate EPS of $0.30. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)